Kidney disease in patients with lupus who are treated with potent drugs that suppress the imune system
Article Abstract:
Cyclophosphamide alone or in combination with methylprednisolone appears to be more effective than methylprednisolone for treating lupus nephritis. Lupus nephritis is a kidney disease caused by lupus, an immunological disease.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
The treatment of lupus nephritis: revisiting Galen
Article Abstract:
Not all patients with lupus nephritis will be cured by cyclophosphamide given either alone or combined with methylprednisolone. Lupus nephritis is a kidney disease caused by lupus, and immunological disorder.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial
Article Abstract:
Cyclophosphamide or cyclophosphamide in combination with methylprednisolone appears to be a better treatment for lupus patients with kidney inflammation compared with methylprednisolone alone. Researchers assigned 82 lupus patients with kidney inflammation to monthly intravenous treatment with either methylprednisolone, cyclophosphamide, or a combination of both. Eighty-five percent of the combination therapy group and 62% of the cyclophosphamide group returned permanently to normal kidney function versus 29% of the methylprednisolone group.
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial
- Abstracts: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial
- Abstracts: Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: A randomized controlled trial